Editas Medicine, Inc. (EDIT) is a leading genome editing company engaged in translating the potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing platforms into a
Editas Medicine, Inc. (EDIT) saw a decrease of 7.04% in aftermarket following the update in SEC filing. However, the last trading session concluded at $19.32
Immutep Limited (NASDAQ: IMMP) shares are trading down -26.19% at $4.2 at the time of writing after reporting that its Chinese partner, EOC Pharma will
Biotech and Major Pharmaceuticals are back in the news with the Covid-19 Pandemic. Life science investors basically endorse developments that might decide the human race’s
Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.